A New Approach to Autoimmune Diseases

D.F. Dowd Nearly one hundred years ago, two German scientists introduced the concept of autoimmune disease;1 it didn't catch on. Indeed, even the investigators themselves were skeptical. To most immunologists, the notion that people might develop immune reactions to their own bodies seemed counterintuitive, even preposterous. "People were very, very reluctant to accept the idea," says Noel Rose, director of the Johns Hopkins University Center for Autoimmune Disease Research and a long-time ex

Written byEugene Russo
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Nearly one hundred years ago, two German scientists introduced the concept of autoimmune disease;1 it didn't catch on. Indeed, even the investigators themselves were skeptical. To most immunologists, the notion that people might develop immune reactions to their own bodies seemed counterintuitive, even preposterous. "People were very, very reluctant to accept the idea," says Noel Rose, director of the Johns Hopkins University Center for Autoimmune Disease Research and a long-time expert in the field.

Then, in the 1950s, two experimental models validated the autoimmune disease concept: one for thyroiditis, spearheaded by Rose, and another for lupus. In recent years, researchers have applied these models to a variety of diseases and conditions; in fact, it might have become a bit too popular. "As often happens in science, the pendulum swung the other way," says Rose. "People began to think of every disease in the book as autoimmune." Autism, Alzheimer disease, even ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies